InvestorsHub Logo
Followers 7
Posts 1112
Boards Moderated 0
Alias Born 11/14/2017

Re: None

Monday, 11/20/2017 10:17:18 AM

Monday, November 20, 2017 10:17:18 AM

Post# of 12427
LXGTF in SHORT: LXGTF is developing
the HeartSentry, a new non-invasive diagnostic tool for accurately measuring
and monitoring cardiovascular health.
• The HeartSentry measures the function of the endothelium – the critical inner
lining of a person’s cardiovascular system.
• The core research and IP portfolio has been exclusively licensed to the
company.
• Lexington is in final stages of releasing the product into clinical studies for FDA
approval.
• The cardiovascular diagnostic market is growing fast and evolving into
personalized medicine.
• The goal is to make HeartSentry the standard of care for cardiologists, general
practitioners, and ultimately patients first line evaluation of cardiovascular
health.
• We seek the participation of dedicated stakeholders and committed
partners who share our vision of the future of cardiovascular personalized
medicine.